NicOx SA
1900 Route des Crêtes, BP 313
Sophia-Antipolis
Cedex
06906
France
Tel: 33-0-4-92387020
Fax: 33-0-4-92387030
Website: http://www.nicox.com/
291 articles about NicOx SA
-
NicOx SA Presents Promising Pre-Clinical Results On An NO-Donating Latanoprost Derivative From Its Glaucoma Collaboration With Pfizer Inc.
2/12/2007
-
NicOx SA Receives 5 Million Euro Payment From Merck & Co., Inc.
1/18/2007
-
NicOx SA ABPM Trial Shows Favorable Blood Pressure Profile For Naproxcinod; Drug Misses Study Goal
12/8/2006
-
NicOx SA Presents Preclinical Results At AHA From Antihypertensive Collaboration With Merck & Co., Inc.
11/14/2006
-
NicOx SA Receives FDA Feedback That No Cardiovascular Outcomes Study Required For Naproxcinod NDA
11/10/2006
-
NicOx SA Naproxcinod Phase 3 OA Trial Meets Primary Endpoints And Shows Encouraging Blood Pressure Profile
10/27/2006
-
NicOx SA Confirms The EMEA Agrees With Its Proposed Naproxcinod Safety Database
10/17/2006
-
NicOx SA Selects NCX 6560 For Development, A New Statin With Broadened Cardiovascular Benefit
9/6/2006
-
NicOx SA Gives Full Details Of Naproxcinod Phase 3 Plan In Osteoarthritis And An Update On Other R&D Programs
9/6/2006
-
NicOx SA Completes Enrolment Ahead Of Schedule In ABPM Trial For Naproxcinod In Hypertensive Subjects
8/3/2006
-
Strong Operational And Financial Achievement Mark A Transforming Six Months For NicOx SA
7/26/2006
-
NicOx SA To Move NCX 4016 Forward In Phase 2 For Diabetes
7/26/2006
-
NicOx SA Announces Patient Enrollment Ongoing In NCX 1000 Phase 2 Study
6/22/2006
-
NicOx SA Receives World Health Organization Acceptance Of Naproxcinod As Generic Name For HCT 3012, First In A New Class Of Treatments For Osteoarthritis
6/19/2006
-
NicOx SA Announces Euro 15 Million Equity Investment By Pfizer Inc.
6/2/2006
-
NicOx SA Partner Topigen Pharmaceuticals Inc. Initiates Phase 2 Program For TPI-1020 In Respiratory Disorders
5/24/2006
-
NicOx SA Completes Enrolment Of Phase 3 Trial For HCT 3012 In Osteoarthritis Ahead Of Schedule
5/24/2006
-
NicOx SA And Grupo Ferrer Internacional S.A. Select Candidate For Development In Dermatology Collaboration
5/16/2006
-
NicOx SA Initiates New Trial To Establish HCT 3012 As Osteoarthritis Treatment With Beneficial Blood Pressure Profile
5/4/2006
-
NicOx SA Announces Fund Raising Of € 45.5 Million By Private Placement
4/28/2006